GCC19CART for Patients With Metastatic Colorectal Cancer

Inclusion Criteria

• •Adults \> 18 years old
• •Clinical and histopathological diagnosis of metastatic colorectal cancer
• •Guanylate Cyclase (GCC) positive disease as determined by immunohistochemistry (IHC). Positivity on staining of archival tumor tissue is adequate.
• •Limited liver disease (less than 7 lesions with largest lesion less than 3 cm)
• •No surgical options with curative intent.
• •Received prior therapy with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy in the advanced or metastatic setting, an anti-vascular endothelial growth factor (anti-VEGF) biological therapy if not contraindicated, and if RAS wild-type an anti-epidermal growth factor receptor (anti-EGFR) therapy in a manner consistent with National Comprehensive Cancer Network (NCCN) guidelines. Treatment must have been discontinued for disease progression or intolerance to therapy.
• •Have at least one extracranial measurable target lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 standard.